Content area
Full Text
The Heart Institute of Spokane and its researchers have filed their first patent application based on basic science research conducted there.
The research, which over the past year or so has been led by Dr. Katherine Tuttle, the Heart Institute's director of research, has the potential to provide new insights into the mechanisms that cause diabetes, heart disease, and kidney disease, Tuttle says.
Now, with an investment from BioGenetic Ventures Inc., of Spokane, Tuttle can advance her research. BioGenetic Ventures, a young Spokane company that invests in the commercialization of emerging scientific research, said in May that it would invest $1 million at the Heart Institute over the next three years. The study Tuttle is leading and one involving gene-therapy, which is being conducted by Dr. William A. Dittman Jr., director of hematology at Sacred Heart Medical Center, are the first two studies to be funded by BioGenetic Ventures. (See related article on...